产品
编 号：F181685
分子式：C17H20ClF4N7O
分子量：449.83
分子式：C17H20ClF4N7O
分子量：449.83
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1536200-31-3
产品详情
生物活性：
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
体内研究：
GNE-9605 (10 and 50 mg/kg; i.p.; once) inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein.GNE-9605 (1 mg/kg, p.o.; 0.5 mg/kg, i.v.; once) displays LRRK2 Ki in the biochemical assay of 2 nM as well as a cellular IC50 of 19 nM. GNE-9605 has a total plasma clearance with excellent oral bioavailability. Animal Model:BAC transgenic mice expressing human LRRK2 protein.
Dosage:10 and 50 mg/kg
Administration:Intraperitoneal injection; once
Result:Inhibited LRRK2 Ser1292 autophosphorylation in a dose-dependent manner.
Animal Model:BAC transgenic mice expressing human LRRK2 protein.
Dosage:1 mg/kg, p.o.; 0.5 mg/kg, i.v.
Administration:Oral administration and intravenous injection; once
Result:Demonstrated a total plasma clearance of 26 mL min-1 kg-1 with excellent oral bioavailability (90%).
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .
体内研究：
GNE-9605 (10 and 50 mg/kg; i.p.; once) inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein.GNE-9605 (1 mg/kg, p.o.; 0.5 mg/kg, i.v.; once) displays LRRK2 Ki in the biochemical assay of 2 nM as well as a cellular IC50 of 19 nM. GNE-9605 has a total plasma clearance with excellent oral bioavailability. Animal Model:BAC transgenic mice expressing human LRRK2 protein.
Dosage:10 and 50 mg/kg
Administration:Intraperitoneal injection; once
Result:Inhibited LRRK2 Ser1292 autophosphorylation in a dose-dependent manner.
Animal Model:BAC transgenic mice expressing human LRRK2 protein.
Dosage:1 mg/kg, p.o.; 0.5 mg/kg, i.v.
Administration:Oral administration and intravenous injection; once
Result:Demonstrated a total plasma clearance of 26 mL min-1 kg-1 with excellent oral bioavailability (90%).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备